NCT00614965 - Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Irinotecan

Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles

DRUG

Cisplatin

Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles

DRUG

Pemetrexed

Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles

Trial Locations (2)

Air Forces Military Hospital, Dep of Medical Oncology, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens